TransCode Therapeutics (NASDAQ:RNAZ – Get Rating) and Lixte Biotechnology (NASDAQ:LIXT – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for TransCode Therapeutics and Lixte Biotechnology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TransCode Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Lixte Biotechnology | 0 | 0 | 0 | 0 | N/A |
TransCode Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 1,478.95%. Given TransCode Therapeutics’ higher probable upside, equities analysts clearly believe TransCode Therapeutics is more favorable than Lixte Biotechnology.
Insider and Institutional Ownership
Risk and Volatility
TransCode Therapeutics has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.
Valuation and Earnings
This table compares TransCode Therapeutics and Lixte Biotechnology’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransCode Therapeutics | N/A | N/A | -$17.57 million | ($1.35) | -0.28 |
| Lixte Biotechnology | N/A | N/A | -$6.31 million | ($0.46) | -1.99 |
Lixte Biotechnology is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares TransCode Therapeutics and Lixte Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransCode Therapeutics | N/A | -139.88% | -117.04% |
| Lixte Biotechnology | N/A | -295.66% | -102.98% |
About TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
About Lixte Biotechnology
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. It engages in the business of utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
